| P2093 | author name string | Peter R Williamson | |
| | John E Bennett | |
| | Anil A Panackal | |
| P2860 | cites work | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| | Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 |
| | Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia | Q28284944 |
| | Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) | Q28298468 |
| | continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis | Q28534551 |
| | The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation | Q33364468 |
| | The role of surgery in the treatment of invasive fungal infection in paediatric haematology patients: a retrospective single-centre survey | Q33412744 |
| | A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). | Q33502338 |
| | Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon | Q33618882 |
| | Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression | Q33697679 |
| | Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients | Q33938201 |
| | Amphotericin B: 30 years of clinical experience | Q34028160 |
| | Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 |
| | Lipopeptide inhibitors of fungal glucan synthase | Q34425782 |
| | Human leukocytes kill Aspergillus nidulans by reactive oxygen species-independent mechanisms. | Q34529560 |
| | Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis | Q34543970 |
| | Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease | Q34574325 |
| | A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group | Q34743741 |
| | Dendritic cells transduced with an adenovirus vector encoding interleukin-12 are a potent vaccine for invasive pulmonary aspergillosis | Q45880890 |
| | Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model. | Q45998758 |
| | Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. | Q46592144 |
| | Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome | Q46758158 |
| | Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion | Q48575634 |
| | Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK. | Q50139687 |
| | Pulmonary pathology of rapidly fatal transfusion-related acute lung injury reveals minimal evidence of diffuse alveolar damage or alveolar granulocyte infiltration. | Q50639553 |
| | Fungal cytoskeleton dysfunction or immune activation triggered by beta-glucan synthase inhibitors: potential mechanisms for the prolonged antifungal activity of echinocandins. | Q51731561 |
| | Current role of echinocandins in the management of invasive aspergillosis. | Q53217028 |
| | Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). | Q53477491 |
| | A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation | Q53927810 |
| | A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease | Q55952474 |
| | A Double-Blind, Randomized, Placebo-Controlled Trial of Itraconazole Capsules as Antifungal Prophylaxis for Neutropenic Patients | Q56970601 |
| | Aspergillus nidulans Infection in Chronic Granulomatous Disease | Q57908366 |
| | Interferon-γ and Granulocyte-Macrophage Colony Stimulating Factor Therapy in Three Patients with Pulmonary Aspergillosis | Q57997454 |
| | Lung Resection in Hematologic Patients With Pulmonary Invasive Fungal Disease | Q59308845 |
| | Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? | Q61546279 |
| | Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections | Q61758371 |
| | Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma | Q72727765 |
| | Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study | Q73767268 |
| | Cytomegalovirus infections in cancer patients receiving granulocyte transfusions | Q74057587 |
| | Systemic arterial embolization in patients with hemoptysis: initial experience with ethylene vinyl alcohol copolymer in 15 cases | Q82316526 |
| | In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network | Q35139558 |
| | Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice | Q35647688 |
| | Aspergillus ustus infections among transplant recipients | Q35793931 |
| | Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. | Q35848799 |
| | Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy | Q36750324 |
| | Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease. | Q36755190 |
| | Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors | Q36870941 |
| | Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. | Q36983268 |
| | New and emerging treatments for fungal infections | Q37026459 |
| | Fungal internal carotid artery aneurysms: successful embolization of an Aspergillus-associated case and review | Q37055204 |
| | Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 |
| | Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria | Q37164085 |
| | Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions | Q37263780 |
| | Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods | Q37374949 |
| | The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. | Q38025819 |
| | The impact of azole resistance on aspergillosis guidelines | Q38066615 |
| | Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial | Q38103680 |
| | Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. | Q38373957 |
| | Enhanced generation of reactive oxygen species by interferon-γ may have contributed to successful treatment of invasive pulmonary aspergillosis in a patient with chronic granulomatous disease | Q39176255 |
| | Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases | Q39419588 |
| | Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 |
| | Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia. | Q39739431 |
| | Inhibitor kappaB and nuclear factor kappaB in granulocyte-macrophage colony-stimulating factor antagonism of dexamethasone suppression of the macrophage response to Aspergillus fumigatus conidia | Q40308360 |
| | High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. | Q40380606 |
| | Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. | Q40395042 |
| | Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. | Q40479359 |
| | Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia | Q40524745 |
| | A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients | Q40577742 |
| | Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity | Q42217419 |
| | In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method | Q42576501 |
| | NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis | Q42599568 |
| | Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus | Q43218415 |
| | Recombinant human interferon-gamma as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease | Q43435358 |
| | Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. | Q43732838 |
| | Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. | Q44059632 |
| | An immunomodulatory activity of micafungin in preclinical aspergillosis | Q44201923 |
| | Aspergillus nidulans is frequently resistant to amphotericin B. | Q44208774 |
| | Itraconazole to prevent fungal infections in chronic granulomatous disease | Q44475171 |
| | Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. | Q44493935 |
| | Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies | Q44519647 |
| | Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases | Q45015455 |
| | Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy | Q45172488 |
| | Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. | Q45223612 |
| P433 | issue | 3 | |
| P921 | main subject | aspergillosis | Q259626 |
| P304 | page(s) | 309-325 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | Current treatment options in infectious diseases | Q26842059 |
| P1476 | title | Treatment options in Invasive Aspergillosis | |
| P478 | volume | 6 | |